Cargando…
Efficacy and safety of low-dose interleukin-2 in combination with methotrexate in patients with active rheumatoid arthritis: a randomized, double-blind, placebo-controlled phase 2 trial
Rheumatoid arthritis (RA) is an aggressive autoimmune arthritis, and current therapies remain unsatisfactory due to low remission rate and substantially adverse effects. Low-dose interleukin-2 (Ld-IL2) is potentially a therapeutic approach to further improve the disease. This randomized, double-blin...
Autores principales: | Zhang, Xiaoying, Miao, Miao, Zhang, Ruijun, Liu, Xu, Zhao, Xiaozhen, Shao, Miao, Liu, Tian, Jin, Yuebo, Chen, Jiali, Liu, Huixin, Zhang, Xia, Li, Yun, Zhou, Yunshan, Yang, Yue, Li, Ru, Yao, Haihong, Liu, Yanying, Li, Chun, Li, Yuhui, Ren, Limin, Su, Yin, Sun, Xiaolin, He, Jing, Li, Zhanguo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8898945/ https://www.ncbi.nlm.nih.gov/pubmed/35250032 http://dx.doi.org/10.1038/s41392-022-00887-2 |
Ejemplares similares
-
Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial
por: He, Jing, et al.
Publicado: (2020) -
Treatment of Active Idiopathic Inflammatory Myopathies by Low-Dose Interleukin-2: A Prospective Cohort Pilot Study
por: Miao, Miao, et al.
Publicado: (2021) -
Therapeutic potential of targeting Tfr/Tfh cell balance by low-dose-IL-2 in active SLE: a post hoc analysis from a double-blind RCT study
por: Miao, Miao, et al.
Publicado: (2021) -
Efficacy and Safety of Low-Dose Interleukin 2 for Primary Sjögren Syndrome: A Randomized Clinical Trial
por: He, Jing, et al.
Publicado: (2022) -
Low-dose IL-2 mitigates glucocorticoid-induced Treg impairment and promotes improvement of SLE
por: Zhou, Haotian, et al.
Publicado: (2023)